Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics

Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics

The deal includes a $310 million upfront payment plus milestones for three IFM Tre assets – one clinical drug for NASH and atherosclerosis and two preclinical molecules.

Source: https://ift.tt/2HQApI9